Irinotecan Accordpharma (Irinotecan Hydrochloride Trihydrate)

Irinotecan Accordpharma acts on malignant cells of the colorectal cancer pathway.

• Colorectal cancer: provides cytotoxic therapy to shrink or control primary tumors.
• Metastatic colorectal cancer: used to reduce tumor burden and improve survival in advanced disease.
• Adjuvant therapy for colorectal cancer: administered after surgery to lower the risk of recurrence.

• Irinotecan Hydrochloride Trihydrate is a topoisomerase I inhibitor. It binds to the DNA‑topoisomerase I complex, preventing relegation of single‑strand DNA breaks that occur during replication. The accumulation of unrepaired DNA breaks leads to replication arrest and apoptosis of rapidly dividing cancer cells.

Irinotecan may cause a range of adverse reactions during treatment.

Common Side Effects

• Diarrhea: often severe and may require antidiarrheal therapy.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Nausea and vomiting: may need anti‑emetic support.
• Fatigue: generalized tiredness affecting daily activities.
• Alopecia: temporary hair loss.
• Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils, a medical emergency.
• Severe colitis or intestinal perforation from uncontrolled diarrhea.
• Hepatic toxicity: elevated liver enzymes or jaundice.
• Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
• Severe mucositis: painful inflammation of the mouth and gastrointestinal lining.

Prior to initiating Irinotecan therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity.

• Renal function: assess creatinine clearance and adjust if necessary.
• Hepatic function: monitor liver enzymes; dose may need modification in impairment.
• Myelosuppression: perform regular complete blood counts to detect neutropenia.
• Diarrhea: implement prophylactic loperamide and educate patients on early reporting.
• Pregnancy: avoid use unless the potential benefit justifies the risk to the fetus.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce irinotecan exposure.
• UGT1A1 inhibitors (e.g., atazanavir): can increase active metabolite levels and toxicity.

Moderate Interactions (Monitor Closely)

• Antiemetics such as ondansetron: may affect metabolism and require dose adjustment.
• Warfarin: potential for increased bleeding risk; monitor INR.
• Other myelosuppressive agents: additive bone‑marrow suppression warrants close blood count monitoring.